StockData
Actuate Therapeutics, Inc. logo

Actuate Therapeutics, Inc. (ACTU) stock

ACTUNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 0/30
$0.25−0.02 (-6.12%)

Close on Nov 17, 2026Market cap $6.04MP/E –Yield –

Actuate Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Actuate Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$16.11M. For fiscal 2025 it was -$19.21M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$19.21M–
FY2024Dec 31, 2024-$21.84M–
FY2023Dec 31, 2023-$21.63M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$2.95M–
Q2 FY2026Jun 30, 2026-$4.41M–
Q1 FY2026Mar 31, 2026-$5.02M–
Q4 FY2025Dec 31, 2025-$3.74M–
Q3 FY2025Sep 30, 2025-$6.68M–
Q2 FY2025Jun 30, 2025-$4.17M–
Q1 FY2025Mar 31, 2025-$4.62M–
Q4 FY2024Dec 31, 2024-$4.77M–
Q3 FY2024Sep 30, 2024-$9.15M–
Q2 FY2024Jun 30, 2024-$2.67M–
Q1 FY2024Mar 31, 2024-$5.25M–
Q4 FY2023Dec 31, 2023-$5.51M–
Q3 FY2023Sep 30, 2023-$5.64M–

More Actuate Therapeutics figures

See a number that looks wrong?